Monopar Therapeutics Inc (MNPR NASDAQ) stock market data APIs
$36.2833
-1.15(-3.2%)
as of July 3, 2025
Try our APIs with
free plan!
Monopar Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Prev. Close
36.2833
Open
35.1346
High
36.2833
Low
34.6945
52 wk Range
1.72-54.3
Market Cap
222 M
Shares Outstanding
6 115 K
EPS
-0.38
Beta
1.011
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Monopar Therapeutics Inc data using free add-ons & libraries
Get Monopar Therapeutics Inc Fundamental Data
Monopar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.5667
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Monopar Therapeutics Inc News
New
Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy
Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan analyst Keay Nakae began coverage of the company’s stock with a “B...
Chardan initiates Monopar stock with buy rating on Wilson disease drug
Investing.com - Chardan Capital Markets initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with a buy rating and a $60 price target, citing potential in its late-stage Wilson disease treatment a...
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmace...
Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%
Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) will be added [https://seekingalpha.com/pr/20123970-monopar-therapeutics-announces-inclusion-in-the-russell-3000-and-russell-2...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
